Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.33 Average PT from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.3333.

CADL has been the topic of a number of recent analyst reports. Lifesci Capital initiated coverage on Candel Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $16.00 price objective on the stock. Citigroup lowered their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its position in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after buying an additional 7,527 shares during the period. Invesco Ltd. bought a new position in Candel Therapeutics in the first quarter worth approximately $59,000. AlphaQuest LLC acquired a new stake in Candel Therapeutics in the first quarter valued at approximately $61,000. Finally, Taylor Financial Group Inc. increased its holdings in shares of Candel Therapeutics by 36.0% during the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock valued at $69,000 after acquiring an additional 3,600 shares in the last quarter. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $5.58 on Friday. The company has a market capitalization of $306.34 million, a price-to-earnings ratio of -9.79 and a beta of -0.93. Candel Therapeutics has a twelve month low of $4.25 and a twelve month high of $13.68. The stock has a fifty day simple moving average of $5.27 and a 200 day simple moving average of $5.54. The company has a quick ratio of 8.25, a current ratio of 8.25 and a debt-to-equity ratio of 0.01.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Sell-side analysts expect that Candel Therapeutics will post -1.47 EPS for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.